This study is testing a new approach for adults with brittle Type 1 Diabetes Mellitus (T1D). It combines transplanted islet cells (specialized cells in the pancreas that make insulin) with an investigational drug called Tegoprubart (AT-1501). Tegoprubart is a monoclonal antibody, a man-made protein designed to help calm your immune system so it's less likely to reject the transplanted islet cells. The goal is to see if these transplanted cells can start producing insulin again, potentially reducing your need for insulin injections. To join, you must be 18-65 years old with a T1D diagnosis for at least 5 years, and able to use continuous glucose monitoring (CGM). The study will measure how many participants become insulin-independent after the transplant. The current recruitment status is unclear.

Study design

This is an interventional study planning to enroll 70 participants. It is testing an experimental drug (Tegoprubart) alongside human pancreatic islet cells.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed to assess insulin independence at Day 75 and Day 365 after the transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.